December 15, 2011
MIGDAL HAEMEQ, IsraelEnzymotec was granted an Australian patent for its Omega-sterols ingredient, a hybrid of naturally occurring phytosterols and omega-3s. The patent (No. AU-0552025002) is for the use of this ingredient as a functional food for diabetics and is one of five different patents covering various properties, composition and methods of use for this ingredient. According to the company, Omega-sterols was clinically proven to be effective for blood lipid control and for supporting healthy levels of both blood triglycerides and LDL-cholesterol (bad cholesterol) in humans.
Omega sterolsTM were also clinically proven to be better than standard sterol-esters since they do not hinder the absorption of certain vitamins, such as Vitamin E. Additionally, there is an initial indication that Omega-Sterols may reduce CRP levels and blood pressure as-well," said Sigalit Zchut, Ph.D., director of R&D for Enzymotec.
Eyal Afergan, Ph.D., omega-3 category manager for Enzymotec, added: This product and its patent applications are an essential part of our strategy to lead the market through innovation and to provide a clear edge to our customers."
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023